Jul 21, 2025
BioXcel Therapeutics Submits Pre-Supplemental New Drug Application Meeting Package in Support of Potential Label Expansion for IGALMI®VIEW RELEASE
Jul 01, 2025
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
May 27, 2025
BioXcel Therapeutics Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaVIEW RELEASE
Stock Information
BioXcel Therapeutics, Inc.
Jul 23, 2025 09:30 AM
MARKET/SYMBOL
Nasdaq:
BTAI
PRICE
1.81
CHANGE
0.01 (0.28%)
